Cellomics is a leading Hong Kong-based biotech company focusing on the development and commercialisation of liquid biopsy products and services for early screening and disease management of cancer. With proprietary microfluidics and nucleic acid detection technology, we offer comprehensive liquid biopsy solutions for precision oncology. Our innovative products for circulating tumor cell enrichment and genetic analysis are manufactured in ISO13485 certified facilities and approved for clinical use in the China market. Cellomics aspires to become a global leader in liquid biopsy and precision medicine, and looks forward to working with international partners to help doctors and
patients in fighting the battle with cancer.